We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.07 | -0.07% | 97.27 | 97.91 | 97.07 | 97.75 | 1,045,674 | 01:00:00 |
From May 2019 to May 2024
By Michael Dabaie
Recro Pharma Inc. (REPH) said Monday it entered into a five-year manufacturing and supply agreement with Novartis (NVS).
Under the agreement, the company's Recro Gainesville division will continue to be the exclusive global supplier to Novartis of Ritalin LA and Focalin XR capsules through 2023, the company said.
The prior Novartis supply contracts were set to expire in late 2019 and mid-2020, respectively, and provided for two revenue components, product manufacturing revenue and royalty revenue. These agreements were consolidated into the new agreement, which provides for product manufacturing revenue that is expected to provide similar total-revenue-per-capsule economics as the two prior revenue components combined.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
February 11, 2019 08:58 ET (13:58 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
